Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer

Introduction: We aimed to determine whether KRAS and BRAF mutant colorectal cancer (CRC) cells exhibit distinct sensitivities to the multi-target angiokinase inhibitor, TKI258 (dovitinib). Materials and methods: We screened 10 CRC cell lines by using receptor tyrosine kinase (RTK) array to identify...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Am J Cancer Res
Главные авторы: Lee, Choong-Kun, Lee, Myung Eun, Lee, Won Suk, Kim, Jeong Min, Park, Kyu Hyun, Kim, Tae Soo, Lee, Kang Young, Ahn, Joong Bae, Chung, Hyun Cheol, Rha, Sun Young
Формат: Artigo
Язык:Inglês
Опубликовано: e-Century Publishing Corporation 2014
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4300687/
https://ncbi.nlm.nih.gov/pubmed/25628921
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы